Esperion Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ESPR and other ETFs, options, and stocks.

About ESPR

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. 

CEO
Sheldon L. Koenig
CEOSheldon L. Koenig
Employees
304
Employees304
Headquarters
Ann Arbor, Michigan
HeadquartersAnn Arbor, Michigan
Founded
1998
Founded1998
Employees
304
Employees304

ESPR Key Statistics

Market cap
727.95M
Market cap727.95M
Price-Earnings ratio
-5.67
Price-Earnings ratio-5.67
Dividend yield
Dividend yield
Average volume
4.84M
Average volume4.84M
High today
$3.06
High today$3.06
Low today
$2.63
Low today$2.63
Open price
$2.65
Open price$2.65
Volume
7.41M
Volume7.41M
52 Week high
$4.18
52 Week high$4.18
52 Week low
$0.6925
52 Week low$0.6925

Stock Snapshot

Esperion Therapeutics(ESPR) stock is priced at $3.08, giving the company a market capitalization of 727.95M. It carries a P/E multiple of -5.67.

During the trading session on 2026-03-10, Esperion Therapeutics(ESPR) shares reached a daily high of $3.06 and a low of $2.63. At a current price of $3.08, the stock is +17.1% higher than the low and still +0.7% under the high.

Trading activity shows a volume of 7.41M, compared to an average daily volume of 4.84M.

Over the past 52 weeks, Esperion Therapeutics(ESPR) stock has traded between a high of $4.18 and a low of $0.69.

Over the past 52 weeks, Esperion Therapeutics(ESPR) stock has traded between a high of $4.18 and a low of $0.69.

ESPR News

TipRanks 49m
Esperion reports Q4 EPS 22c, consensus 28c

Reports Q4 revenue $168.4M, consensus $166.12M. “2025 was a defining year for Esperion (ESPR). We delivered strong growth in our U.S. cardiovascular franchise,...

TipRanks 49m
Esperion sees 2026 operating expenses $225M-$255M vs. $343M in 2025

06:03 EDT Esperion (ESPR) sees 2026 operating expenses $225M-$255M vs. $343M in 2025 Published first on TheFly – the ultimate source for real-time, market-movi...

TipRanks 6d
Balanced Risk-Reward Keeps Esperion at Hold Amid Complex Corstasis Acquisition and CHF Market Challenges

Esperion, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Paul Choi from Goldman Sachs maintained a Hold rating on the...

Analyst ratings

71%

of 7 ratings
Buy
71.4%
Hold
14.3%
Sell
14.3%

More ESPR News

Benzinga 7d
Esperion Acquires Enbumyst Maker Corstasis

Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares are down during Tuesday’s premarket session as the company announced a definitive agreement to acquire Corstasi...

Esperion Acquires Enbumyst Maker Corstasis
TipRanks 7d
Esperion to Acquire Corstasis, Expanding Heart Failure Portfolio

The latest update is out from Esperion ( (ESPR) ). On March 2, 2026, Esperion Therapeutics, Inc. signed a definitive agreement to acquire privately held Corsta...

TipRanks 7d
Esperion signs definitive acquisition of Corstasis Therapeutics

Esperion (ESPR) has entered into a definitive agreement to acquire Corstasis Therapeutics, a privately-held, commercial-stage biopharmaceutical company advancin...

People also own

Based on the portfolios of people who own ESPR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.